Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on March 12, 2014. The report documents corporate governance actions taken in connection with the closing of the Company's initial public offering (IPO) of common stock. Note: The request metadata references "Neurogene Inc.," but the filing text explicitly identifies the registrant as Aquinox Pharmaceuticals, Inc.
Financial Metrics
This filing is a current report regarding corporate amendments and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Amended and Restated Certificate of Incorporation: Filed with the Delaware Secretary of State on March 12, 2014, effective upon the closing of the IPO.
- Amended and Restated Bylaws: Adopted effective March 12, 2014, in connection with the IPO closing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document strictly reports the execution of the Restated Certificate and Restated Bylaws as previously approved by the board and stockholders.
Key Facts for Investor Verification
- Verify the closing status and terms of the initial public offering referenced in the Registration Statement on Form S-1 (File No. 333-193615).
- Review the attached Exhibit 3.1 (Amended and Restated Certificate of Incorporation) and Exhibit 3.2 (Amended and Restated Bylaws) for specific changes to corporate governance.
- Confirm the identity of the registrant as Aquinox Pharmaceuticals, Inc., distinct from Neurogene Inc.